Tardive dyskinesia
Drug-induced movement disorder · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Involuntary, often orofacial, choreiform or stereotypic movements caused by chronic exposure to dopamine receptor-blocking drugs, especially antipsychotics and metoclopramide. May be irreversible, so prevention and early recognition are key, with VMAT2 inhibitors as targeted treatment.
Red flags
- Respiratory or oesophageal dyskinesia compromising breathing/swallowing
- Severe tardive dystonia
- Worsening on drug withdrawal
- Coexisting depression/suicidality with VMAT2 inhibitors (tetrabenazine)
- Diagnostic uncertainty with progressive course
Assessment
Differential diagnosis
- Huntington's disease and other chorea
- Acute dystonic reaction
- Tardive dystonia or akathisia
- Spontaneous orofacial dyskinesia (edentulous)
- Functional movement disorder
- Wilson's disease
Investigations
- Detailed drug history (antipsychotics, metoclopramide, prochlorperazine)
- Standardised rating (AIMS - Abnormal Involuntary Movement Scale)
- Exclude other chorea (copper studies, autoimmune screen if atypical)
- MRI brain if focal or atypical features
- Review indication for the causative drug
Management
- Identify chronic dopamine-blocker exposure and characterise the movements
- Document severity with the AIMS scale for monitoring
- Review the ongoing need for the offending drug with the prescriber
- Where possible, reduce or switch to a lower-risk agent (e.g. clozapine, quetiapine)
- Avoid abruptly stopping antipsychotics which can transiently worsen movements
- Start a VMAT2 inhibitor for troublesome persistent tardive dyskinesia
- Avoid anticholinergics which worsen tardive dyskinesia (unlike acute dystonia)
- Monitor response and psychiatric stability
- Educate the patient and document informed consent for antipsychotic continuation
- Refer refractory cases for specialist or botulinum toxin treatment
Drugs & doses
Valbenazine 40 mg PO daily, increase to 80 mg daily (VMAT2 inhibitor)
Deutetrabenazine 6 mg PO BD titrated to 24 mg BD (max 48 mg/day)
Tetrabenazine 12.5-25 mg PO TDS as alternative
Clozapine switch for antipsychotic-requiring patients
Botulinum toxin for focal tardive dystonia
Disposition
Joint neurology-psychiatry management. Specialist referral for VMAT2 inhibitor initiation and refractory cases.
Complications & pitfalls
- Irreversible involuntary movements
- Social stigma and functional impairment
- Dental and oral trauma
- Depression (tetrabenazine)
- Respiratory/swallowing dyskinesia
Exam pearls
- Anticholinergics help acute dystonia but worsen tardive dyskinesia
- VMAT2 inhibitors (valbenazine, deutetrabenazine) are the evidence-based treatment
- Prevention by using the lowest effective antipsychotic dose is paramount
- Do not stop antipsychotics abruptly; this can unmask or worsen movements
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.